Raymond James resumed coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with an “outperform” rating and $7 (Canadian) price target. The stock closed at $1.36 on June 8. Eupraxia’s lead clinical candidate, EP-104IAR...
Search results for - Raymond james
Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)
Raymond James downgraded Cardiol Therapeutics (TSX:CRDL) to “market perform” from “outperform” and trimmed its price target to $4 (Canadian) from $5, citing a slower than expected enrollment in Cardiol’s LANCER clinical...
Raymond James starts Medexus at OP; PT $5.50 (Canadian)
Raymond James initiated coverage of Medexus Pharmaceuticals (TSX:MDP) with an “outperform” rating and price target of $5.50 (Canadian). The stock closed at $3.32 on Feb. 18. Medexus is a fully integrated, specialty...
Raymond James ups Opsens to strong buy; PT $6 (Canadian)
Raymond James upgraded Opsens (TSX:OPS) to “strong buy” from “outperform” with a price target of $6 (Canadian) after the company said its TAVR trial was “very successful.” The stock was quoted at $2.99, down 40 cents...
Raymond James ups Alpha Cognition PT to $3.50 (Canadian)
Raymond James raised its price target for Alpha Cognition (TSXV:ACOG) to $3.50 (Canadian) from $2.50 and maintained its “outperform” rating after the FDA accepted Alpha’s IND application to proceed into a pivotal...
Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO
Raymond James gave winning marks to Profound Medical‘s (NASDAQ:PROF; TSX:PRN) TULSA-PRO device, compared with the Focal One HIFU device from France’s EDAP TMS SA (NASDAQ:EDAP), in a head-to-head comparison study...
Raymond James ups HLS Therapeutics to OP; PT to $26 (Canadian)
Raymond James upgraded HLS Therapeutics (TSX:HLS) to “outperform” from “market perform” and raised its price target to $26 (Canadian) from $24 after Pfizer agreed to co-market HLS’s cardiovascular drug...
Raymond James starts Alpha Cognition at OP; PT $2.50 (Canadian)
Raymond James initiated coverage of Alpha Cognition (TSXV:ACOG) with an “outperform” rating and price target of $2.50 (Canadian). The stock closed at 80 cents on June 2. Alpha is in the late stages of clinical...
Raymond James ups Cardiol Therapeutics to OP from MP
Raymond James upgraded Cardiol Therapeutics (TSX:CRDL) to “outperform” from “market perform,” citing enrollment of the first patient in a Phase 2/3 clinical trial investigating the cardioprotective properties of...
Raymond James starts Eupraxia Pharma at OP; PT $13 (Canadian)
Raymond James initiated coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with an “outperform” rating and a $13 price target. The stock closed at $6.21 on April 12. Eupraxia aims to address the growing burden of...